Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 28 2024 - 8:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2024 (Report No. 9)
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On
October 28, 2024, NLS Pharmaceutics Ltd., or the Registrant, issued a press release titled: “NLS Pharmaceutics Ltd. Regains Full
Compliance with Nasdaq Listing Requirements.” A copy of this press release is furnished herewith as Exhibit 99.1.
This
Report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-282788,
333-262489, 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
NLS Pharmaceutics Ltd. |
|
|
|
Date: October 28, 2024 |
By: |
/s/ Alexander Zwyer |
|
|
Name: |
Alexander Zwyer |
|
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
NLS Pharmaceutics Ltd. Regains Full Compliance
with Nasdaq Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / October 28,
2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical
company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders,
today announced that it has received notice from the Nasdaq Stock Market LLC (“NASDAQ”) informing the Company that it has
regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).
“We are pleased to report that Nasdaq has
recognized our full compliance with their listing requirements,” said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
“Their confirmation follows our successful efforts to improve our balance sheet, including raising new capital and implementing
a reverse share split.”
About NLS
Pharmaceutics Ltd.
NLS is a global development-stage biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development
of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered
in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing
product candidates. For more information, please visit www.nlspharma.com.
Contact:
Investor Relations Contact
InvestorRelations@nls-pharma.com
www.nlspharma.com
NLS Pharmaceutics (NASDAQ:NLSPW)
Historical Stock Chart
From Sep 2024 to Oct 2024
NLS Pharmaceutics (NASDAQ:NLSPW)
Historical Stock Chart
From Oct 2023 to Oct 2024